OncoMatch/Clinical Trials/NCT04999761
AB122 Platform Study
Is NCT04999761 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments for advanced or metastatic solid tumor.
Treatment: AB122 · AB122 · TAS-116 · AB122 · TAS-116 · AB122 · TAS-116 · AB122 · TAS-120 · AB122 · TAS-115 · AB122 · TAS-115 · AB122 · TAS-102 · Ramucirumab · AB122 · TAS-102 · Bevacizumab · AB122 · AB122 · TAS-120 · Fluorouracil · Cisplatin · AB122 · TAS-120 · AB154 · AB122 · TAS-120 · Fluorouracil · Carboplatin · Cisplatin · AB122 · TAS-120 · AB154 · AB122 · TAS-120 · Carboplatin · nab-Paclitaxel · AB122 · TAS-120 · Cisplatin · Gemcitabine · AB122 · TAS-120 · nab-Paclitaxel · Gemcitabine — This is a phase 1, non-randomized open-label, multicenter platform study designed to evaluate the tolerability and safety of AB122 in patients with malignancies specified in each cohort.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Pancreatic Cancer
Colorectal Cancer
Non-Small Cell Lung Carcinoma
Gastric Cancer
Sarcoma
Esophageal Carcinoma
Head and Neck Squamous Cell Carcinoma
Cholangiocarcinoma
Biomarker criteria
Required: KRAS wild type
Wild type is defined as v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) (exon 2, 3 and 4) and neuroblastoma RAS viral (v-ras) oncogene homolog (NRAS) (exon 2, 3 and 4) wild type
Required: NRAS wild type
Wild type is defined as v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) (exon 2, 3 and 4) and neuroblastoma RAS viral (v-ras) oncogene homolog (NRAS) (exon 2, 3 and 4) wild type
Required: PD-L1 (CD274) ≥ 50% tumor proportion score (≥ 50% TPS)
Has PD-L1 (≥ 50% tumor proportion score) in tumor tissue sample as determined at a local laboratory
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: immune checkpoint inhibitor
Exception: except for cohort B-3, C-1, D-1 tolerability part and E-1
Prior treatment with an anti-PD-L1 anti-PD-1, anti-CTLA-4, or other ICI or agonist as monotherapy or in combination (except for cohort B-3, C-1, D-1 tolerability part and E-1)
Lab requirements
Blood counts
ANC ≥ 1500 /mm3; Platelet count ≥ 100000 /mm3; Hemoglobin value of ≥ 9.0 g/dL
Liver function
AST and ALT ≤ 3 × ULN; or if a patient with documented liver metastases, AST and ALT ≤ 5 × ULN; T-Bil of ≤ 1.5 × ULN
AST and ALT ≤ 3 × ULN; or if a patient with documented liver metastases, AST and ALT ≤ 5 × ULN; T-Bil of ≤ 1.5 × ULN; ANC ≥ 1500 /mm3; Platelet count ≥ 100000 /mm3; Hemoglobin value of ≥ 9.0 g/dL
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify